Stardocs Success Stories
Xlear Nasal Spray

FDA Warns Against Unproven MS Treatment

Written by Michael Richardson

The FDA issued a warning to health care professionals and their patients on recently about injuries and death associated with a multiple sclerosis (MS) treatment called “liberation therapy” by some.

“Liberation therapy,” an experimental procedure, is meant to treat chronic cerebrospinal venous insufficiency (CCSVI), a narrowing of veins in the neck and chest, which may be a cause of MS or may contribute to the disease’s progression. The recent FDA news release, however, said “studies exploring a link between MS and CCSVI are inconclusive, and the criteria used to diagnose CCSVI have not been adequately established.” The procedure uses balloon angioplasty devices or stents to widen the narrowed veins in the chest and neck. But the procedure can lead to a myriad of health problems, according to the FDA.

“The FDA has learned of death, stroke, detachment and migration of the stents, damage to the treated vein, blood clots, cranial nerve damage and abdominal bleeding associated with the experimental procedure. Balloon angioplasty devices and stents have not been approved by the FDA for use in treating CCSVI.”

The cause of MS remains unknown, though its damaging effects are well understood. The disease damages the ability of nerve cells in the brain and spinal cord to communicate with each other, and can lead to a host of problems, such as loss of sensitivity, loss of balance, speech issues, cognitive impairment and depression, to name a few. MS gradually deteriorates neurological function.

Article Reviewed: June 1, 2012
Copyright © 2014 Healthy Magazine

Michael Richardson is an experienced writer, reporter, and interviewer. His writing has appeared in many publications, including KSL, Deseret News, BYU's Family Connections Magazine, and now, Healthy Magazine. Michael is involved in promoting the ideas of social entrepreneurship and solution journalism. And, when he's not saving the planet through his social journalistic ventures, Michael revels in exploring the latest developments in the field of healthcare, its history, its advancements, and where we will be tomorrow.

Find him on

VISIT WEBSITE

Related Articles
The safety of long-acting beta agonists has come under serious scrutiny recently.
Article Reviewed: June 7, 2013
Important information that could save your life
Article Reviewed: August 15, 2012
USA Today report shows that people need to talk to their doctors about treatments
Article Reviewed: June 20, 2013
Brigham Young University Takes on Pfizer Over Drug Celebrex and Wins $450 Million Settlement
Article Reviewed: August 8, 2012
Some things about water that make you go 'hmmm...'
Article Reviewed: November 14, 2013